Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ceralasertib - AstraZeneca/University of Pennsylvania

Drug Profile

Ceralasertib - AstraZeneca/University of Pennsylvania

Alternative Names: AZD-6738

Latest Information Update: 12 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca; University of Pennsylvania
  • Developer AstraZeneca; Samsung Medical Center; University of Pennsylvania
  • Class Antineoplastics; Imines; Morpholines; Pyrimidines; Small molecules
  • Mechanism of Action ATR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Gastric cancer; Gynaecological cancer; Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer
  • Phase I/II Chronic lymphocytic leukaemia; Solid tumours
  • Phase I Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
  • Preclinical Diffuse large B cell lymphoma
  • No development reported B-cell lymphoma; Lymphoid leukaemia

Most Recent Events

  • 01 Nov 2019 Phase-II clinical trials in Gynaecological cancer (Combination therapy, Second-line therapy or greater, Metastatic disease, Recurrent) in United Kingdom (PO) (NCT04065269)
  • 26 Oct 2019 Pharmacodynamics data presented at the International Conference on Molecular Targets and Cancer Therapeutics 2019 (AACR-NCI-EORTC-2019)
  • 30 Sep 2019 AstraZeneca initiates a ATRiUM phase I trial for Solid tumours (Combination therapy, Metastatic disease, Inoperable/Unresectable, Late-stage disease) in the UK (PO) (NCT02264678) (EudraCTNCT02264678)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top